Queensland biotechnology company Microbio expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market.
US based Landrich Group is managing the trials at four locations in the USA, South America, India and Australia, undertaking a performance evaluation of Microbio InfectID assays.
Read more in the media release: 220412_Independent assessment of Microbio’s BSI test expected to be completed in May
Microbio is pleased to share this profile published in The Yield, Spoke Corporate’s Investor and Industry News. Author Simon Shepherdson has perfectly captured Microbio’s exciting history and big plans for the future. https://spokecorporate.com/diagnostic-technology-set-to-change-the-world/
Microbio is pleased to share the Case Study published by Life Sciences Queensland detailing the recent Federal Government Accelerating Commercialisation Grant and commercialisation progress of its pathogen detection products. Read more at: https://www.lsq.com.au/case-study/microbio-new-diagnostic-tests-to-improve-the-identification-of-pathogens/
Microbio Pty Ltd, an Australian-owned biotech company has been awarded a Federal Government Accelerating Commercialisation Grant to commercialise Microbio’s InfectID-Blood Stream Infection (BSI) diagnostic assay. Read more in the full media release.